Bacteria Protein Sales 
pharmaphorum
DECEMBER 4, 2020
Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets. OspA is one of the most dominant surface proteins expressed by the bacteria when present in the ticks that spread the disease.
Pharmaceutical Technology
MARCH 10, 2023
Pharmaceutical and biotechnology industries widely use freeze-drying systems to protect vaccines, antibodies, antibiotics such as penicillin, blood plasma, proteins, enzymes, hormones, viruses, and bacteria from heat and minimise their biological activity.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
DECEMBER 12, 2023
Less than a week after the approval, Novartis shared results from its APPEAR-C3G Phase III study of patients with C3 glomerulopathy (C3G) that showed iptacopan led to clinically meaningful reduction in proteinuria (protein in the urine) compared to placebo after six months of use.
Delveinsight
JULY 26, 2021
The major factor driving the sales of antibiotics in the Uncomplicated Urinary Tract Infections market revolves around antibiotic resistance. Besides Gepotidacin, GSK is also evaluating another asset GSK3882347 , that targets an adhesive protein found on the surface of E. coli bacteria called FimH.
pharmaphorum
JUNE 20, 2022
Valneva is on the hook for 40% of development costs, up from 30%, but also stands to receive milestone payments of up to $100 million based on sales performance which were not included in the original agreement. The shot targets the outer surface protein A (OspA) of the Borrelia burgdorferi bacteria that causes Lyme disease.
XTalks
MAY 18, 2023
Cronobacter sakazakii , the bacteria linked to recent baby formula shortages and the Abbott infant formula recall, could soon join the federal disease watchlist. Fairlife milk boasts 50 percent higher levels of protein and calcium while containing 50 percent less sugar compared to traditional milk, while also being lactose-free.
pharmaphorum
MAY 31, 2022
Last year, Affinivax reported positive phase 2 results with ASP3772, which targets 24 of the common serotypes of Streptococcus pneumoniae – a bacteria which causes non-invasive illnesses like pneumonia, sinusitis and middle ear infections, as well as invasive diseases like meningitis. billion in sales last year.
Expert insights. Personalized for you.
119 
Let's personalize your content